Monalisa Ghosh, MD
Medical Oncology · Ann Arbor, MINPI 1902123284
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,320 of the $8,898 with a category attached, or 93.5%. 3 manufacturers reported payments, led by Novartis at 55.1% of the total.
Across 6 payments — averaging $1483.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- E.r. Squibb & Sons, L.L.C.$3K
- Bristol Myers Squibb$578
Across 83 payments — averaging $32,346 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1.5M
- Novartis$646K
- E.r. Squibb & Sons, L.L.C.$125K
- Incyte Corporation$120K
- Takeda Pharmaceuticals U.S.A., Inc.$118K
- Janssen Research & Development, LLC$69K
- plus $57K from 1 others
What the payments were for
- Consulting fees$8,32094%
- Travel & lodging$4745%
- Food & beverage$1041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $4,900 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,420 |
| Bristol Myers Squibb | 4 | $578 |
How this compares
$8,898 in reported general payments places this provider in the 65th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 44 | $483,982 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $92,808 |
| Posaconazole | 26 | $42,802 |
| Tacrolimus | 15 | $2,334 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,309 |
| Acyclovir | 44 | $1,303 |
| Azithromycin | 18 | $456 |
| Hydrocortisone | 11 | $455 |
| Montelukast Sodium | 12 | $226 |
| Famotidine | 17 | $139 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ann Arbor
- Harry ErbaAnn Arbor$1.1M
- Frank WeinbergAnn Arbor$195K
- Francis WordenAnn Arbor$142K
- Maha HussainAnn Arbor$114K
- Moshe TalpazAnn Arbor$83K
- Vaibhav SahaiAnn Arbor$80K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.